Zanubrutinib with del(17p) in treatment-naive CLL / SLL
June 24, 2025
Zanubrutinib, a newer BTK inhibitor, showed 60-month progression-free survival (PFS) in frontline high-risk CLL / SLL patients with del(17p)
Zanubrutinib, a newer BTK inhibitor, showed 60-month progression-free survival (PFS) in frontline high-risk CLL / SLL patients with del(17p)
Combining zanubrutinib with venetoclax results in nearly a 100% response rate in frontline CLL / SLL patients.
Patients with CLL / SLL who were treated with zanubrutinib continue to experience deep sustained responses six years out with no new safety issues.
With five years of follow-up, zanubrutinib continues to provide greater progression-free survival in treatment-naïve patients with CLL / SLL.
Patients with CLL who were able to rapidly clear measurable residual disease (MRD) needed less treatment and experienced longer remissions.
The combination of sonrotoclax and zanubrutinib was well-tolerated and produced high rates of undetectable disease in patients with treatment-naïve CLL.
Combining the new BCL2 inhibitor sonrotoclax with the BTK inhibitor zanubrutinib produced an overall response rate of 97% in relapsed CLL / SLL.
The combination therapy of tislelizumab plus zanubrutinib is effective and well-tolerated for patients with Richter’s transformation.
Zanubrutinib may be taken alone as a preferred initial (first-line) treatment, or alone as a second- or third-line treatment.
© 2025 CLL Society. All Rights Reserved.
Legal | Privacy Policy | Corporate Giving Policy
Terms & Conditions | Report a Bug | Site Design
CLL Society Inc. is a patient–centric, physician–curated nonprofit organization focused on patient education, support, and research. Dedicated to addressing the unmet needs of the chronic lymphocytic leukemia (CLL) and related blood cancer communities, we explain the rapidly changing therapeutic landscape and the importance of clinical trials, support and build patient networks, engage in research, and educate providers and patients.
CLL Society is a registered 501(c)(3) tax-exempt nonprofit organization. All donations are tax-deductible to the greatest extent as allowed under federal law. CLL Society’s tax ID number is 46-4131354.
1454 Melrose Avenue, Ste. 1-247
Chula Vista, CA 91911